Jubilant Therapeutics Inc. announces first patient dosing in global clinical trials
- Posted on October 25, 2024
- By Financial Express
- 2 Views
Jubilant Therapeutics Inc. announces first patient dosing in global clinical trials
BI-778 is a unique substrate competitive brain penetrant PRMT5 inhibitor that has shown no adverse effects in preclinical setting, the company said in a statement.
